{"product_id":"orion-pestle-analysis","title":"Orion PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic trends, and technological disruption are shaping Orion’s strategic outlook—our concise PESTLE highlights risks and opportunities you need to know; purchase the full analysis for the complete, actionable deep dive ready for investor decks and strategy sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU Pharmaceutical Legislation Reform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe revised EU pharmaceutical framework, effective late 2025, shortens regulatory data protection from 8+2 years toward an average of 6 years, pressuring Orion’s revenue runway for new CNS and oncology drugs where launch NPV projections fall by an estimated 12–18% under shorter exclusivity.\u003c\/p\u003e\n\u003cp\u003eNew incentives targeting unmet needs—grants, accelerated assessments, and up to €200m joint funding programs—offer Orion opportunity to offset lost exclusivity, especially given its neurology pipeline representing ~35% of R\u0026amp;D projects.\u003c\/p\u003e\n\u003cp\u003eThis political shift forces Orion to prioritize faster EU launch sequencing, adaptive pricing and lifecycle strategies, and increased partnering to preserve commercial viability across the single market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinnish Healthcare Funding Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs Finland's domestic leader, Orion is sensitive to government budget shifts: the 2025 state budget cut wellbeing services counties' discretionary spending by about 1.1% (≈€130m), which affects hospital procurement and Orion's home-market sales.\u003c\/p\u003e\n\u003cp\u003ePolitical decisions on reimbursement and specialized medicine funding—Finland reimbursed medicines at €1.9bn in 2024—influence revenue mix for Orion's proprietary drugs.\u003c\/p\u003e\n\u003cp\u003eReforms to the national health insurance scheme in 2026 prioritize cost-effective generics, with generic substitution rates targeted to rise from 36% in 2024 to ~45% by 2026, pressuring Orion's patented portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Supply Chain Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOngoing geopolitical tensions in Eastern Europe and rising EU trade frictions with China and the US mean Orion must strengthen political risk management; EU goods trade fell 3.5% YoY in 2024, aggravating supply volatility.\u003c\/p\u003e\n\u003cp\u003eOrion's active pharmaceutical ingredient sourcing is vulnerable if sanctions expand—global API shortages in 2024 pushed lead times up 22%, raising input cost pressures.\u003c\/p\u003e\n\u003cp\u003eMaintaining a diversified supplier base and nearshoring options for Finland operations is essential: 58% of EU firms reported supply-chain relocation plans in 2024 to reduce geopolitical exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Trade Protectionism\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe rise of protectionism in markets like the US and China threatens Orion’s expansion; US tariffs could target pharma imports and China’s localization push (over 20% of Chinese pharma sales favored local production in 2024) may force costlier onshore manufacturing.\u003c\/p\u003e\n\u003cp\u003eTariff or local-manufacturing requirements could raise COGS and cut margins—US import duties on some drugs rose 5–10% in 2023–24—so Orion must track bilateral trade deals and diplomatic shifts to retain access to these growth markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS\/China protectionism rising; 20%+ China preference for local pharma (2024)\u003c\/li\u003e\n\u003cli\u003eUS import duties increased 5–10% on some drugs (2023–24)\u003c\/li\u003e\n\u003cli\u003eLocalized manufacturing may raise COGS, squeeze margins\u003c\/li\u003e\n\u003cli\u003eMonitor trade agreements and diplomatic relations continuously\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental R\u0026amp;D Incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFinnish government and EU R\u0026amp;D programs supplied Orion with roughly EUR 45–60 million in grants and tax credits from 2020–2024, helping offset heavy development costs for respiratory and CNS candidates.\u003c\/p\u003e\n\u003cp\u003eThese incentives—including Business Finland funding and EU Horizon grants—support early-stage trials and reduce burn rates on novel therapeutics.\u003c\/p\u003e\n\u003cp\u003eA political shift deprioritizing life sciences could jeopardize Orion’s pipeline funding and increase time-to-market and capital needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2020–2024 grants\/tax credits ~EUR 45–60m\u003c\/li\u003e\n\u003cli\u003eKey sources: Business Finland, Horizon Europe\u003c\/li\u003e\n\u003cli\u003eRisk: policy shift → higher capex and delayed approvals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShorter EU exclusivity trims launch NPV 12–18%; grants, rebates and tariffs reshape pharma margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShorter EU exclusivity (avg ~6 yrs vs 8+2) cuts launch NPV 12–18%; EU incentives up to €200m and Finland\/EU grants €45–60m (2020–24) partially offset risks. Finland 2025 budget trimmed −1.1% (~€130m) and 2024 medicine reimbursement €1.9bn; generics share target rises 36%→45% by 2026, increasing margin pressure. Supply-chain lead times +22% (2024); US\/China protectionism and 5–10% pharma tariff rise add trade risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU exclusivity\u003c\/td\u003e\n\u003ctd\u003e~6 yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNPV impact\u003c\/td\u003e\n\u003ctd\u003e−12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrants 2020–24\u003c\/td\u003e\n\u003ctd\u003e€45–60m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinland med spend 2024\u003c\/td\u003e\n\u003ctd\u003e€1.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics target 2026\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI lead-time rise 2024\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect the Orion across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—each backed by current data and forward-looking insights to support scenario planning and strategy design for executives, investors, and entrepreneurs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOrion’s PESTLE summary delivers a clean, shareable snapshot of external risks and opportunities—visually grouped by category and editable with notes—so teams can quickly align on market positioning and drop concise insights into presentations or planning sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D Cost Inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D Cost Inflation: Specialized labor rates rose ~8–10% YoY in 2024–2025, while advanced lab equipment capex increased ~12%; combined, Orion faces a projected +15–20% uplift in oncology R\u0026amp;D spend versus 2023, pressuring operating margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith sales in 100+ countries, Orion faces currency risk as a strong euro lowered FY2024 US dollar-translated revenues by an estimated 3.2%, hitting Nubeqa export contributions to the US market where oncology sales reached €210m in 2024.\u003c\/p\u003e\n\u003cp\u003eEuros appreciation versus the dollar averaged 6.5% in 2024, reducing reported international sales; management reports using forwards and options covering ~60% of projected FX exposure into 2025.\u003c\/p\u003e\n\u003cp\u003eGeographic diversification—US sales rose 18% y\/y in 2024—combined with hedging mitigates volatility, but persistent euro strength could pressure reported margins and EPS.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Austerity Measures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMany EU states tightened price controls and mandated generic substitution in 2024–25; e.g., Germany expanded reference pricing and France capped growth of drug reimbursements to under 2% in 2024, pressuring margins. These measures curb Orion’s ability to charge premiums for respiratory and neurology therapies, as average reimbursement discounts vs list price reached 12–18% in 2024. Orion must prove superior clinical value and cost-effectiveness to secure reimbursement and maintain revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAt end-2025, a US federal funds effective rate near 5.25% raises Orion’s weighted average cost of capital, increasing financing costs for planned API plant upgrades and M\u0026amp;A; 2025 capex sensitivity shows a 150–250 bps hike can raise annual interest expense by $12–18m on $400m of debt.\u003c\/p\u003e\n\u003cp\u003eAnalysts track Orion’s debt-to-equity (~0.6x in 2025) and free cash flow coverage (\u0026gt;1.2x) to evaluate resilience to prolonged high rates and refinancing risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-2025 policy rate ~5.25% — higher borrowing costs for capex\u003c\/li\u003e\n\u003cli\u003e150–250 bps rate shock ≈ $12–18m extra interest on $400m debt\u003c\/li\u003e\n\u003cli\u003eDebt-to-equity ~0.6x; FCF coverage \u0026gt;1.2x — monitor refinancing risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Growth Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpsoutheast asia and parts of latin america are growing at gdp in offering orion generics veterinary lines rising demand as middle-class populations expand to combined capture requires localized marketing partnerships outcompete domestic firms.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGDP growth: SE Asia ~4–5%, LATAM ~2.5–3.5% (2024–25)\u003c\/li\u003e\n\u003cli\u003eMiddle-class population ~1.7bn combined\u003c\/li\u003e\n\u003cli\u003eAction: strategic partnerships, localization, competitive pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/psoutheast\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D inflation, euro strength and rate shocks squeeze margins as EM growth offsets pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising R\u0026amp;D inflation (+15–20% vs 2023), euro strength (avg +6.5% in 2024; -3.2% USD-rev drag FY2024), higher rates (fed ~5.25% end-2025; 150–250bps shock → $12–18m extra interest on $400m), debt\/equity ~0.6x, FCF coverage \u0026gt;1.2x, EU price controls cutting reimbursements 12–18%, SE Asia\/LATAM GDP ~4–5%\/2.5–3.5% with ~1.7bn rising middle class.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D cost uplift\u003c\/td\u003e\n\u003ctd\u003e+15–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuro vs USD\u003c\/td\u003e\n\u003ctd\u003e+6.5% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed rate\u003c\/td\u003e\n\u003ctd\u003e~5.25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\/equity\u003c\/td\u003e\n\u003ctd\u003e~0.6x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eOrion PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Orion PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751222063481,"sku":"orion-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/orion-pestle-analysis.png?v=1772229003","url":"https:\/\/matrixbcg.com\/products\/orion-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}